Related Experiment Video
Updated: May 5, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Case Report: Asymptomatic macular edema in ozanimod
Valentina Annamaria Mauceri1, Tommaso Torresin1,2, Elisa Basili1,3
1Department of Neurosciences, University of Padua, Padua, Italy.
Ozanimod, a sphingosine-1-phosphate receptor (S1PR) modulator, can cause asymptomatic macular edema (ME) in multiple sclerosis (MS) patients. Regular eye monitoring is crucial, especially for those with prior retinal conditions, to detect this rare adverse event early.
Area of Science:
- Ophthalmology
- Neurology
- Pharmacology
Background:
- Relapsing-remitting multiple sclerosis (RRMS) management involves immunomodulatory therapies.
- Sphingosine-1-phosphate receptor (S1PR) modulators, like ozanimod, are used for MS treatment.
- Ocular adverse events, including macular edema (ME), are potential side effects of S1PR modulators.
More Related Videos
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Nephrotic Syndrome II : Assessment and Medical Management
Cerebral Edema ll: Pathophysiology
Cytotoxic Edema: Pathophysiology